Bellerophon provides clinical program update and reports fourth quarter and full-year 2020 financial results

Warren, n.j., march 11, 2021 (globe newswire) -- bellerophon therapeutics, inc. (nasdaq: blph) (“bellerophon” or the “company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the fourth quarter and year ended december 31, 2020.
BLPH Ratings Summary
BLPH Quant Ranking